Uncategorized

Donanemab Slows Clinical Progression in Early Alzheimer Disease

1 year ago
by David Miller
948 Views

MONDAY, July 17, 2023 — Donanemab slows clinical progression among participants with early symptomatic Alzheimer disease and amyloid and tau pathology, according to a study published online July 17 in the Journal of the American Medical Association…

MONDAY, July 17, 2023 — Donanemab slows clinical progression among participants with early symptomatic Alzheimer disease and amyloid and tau pathology, according to a study published online July 17 in the Journal of the American Medical Association…Original Article

You may also like

About the author

David Miller

a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.

View all posts

Don`t Leave Yet!

Thank you!

[mwai_chat window="true" fullscreen="true"]